News & Press Releases
Filter by:
Mintz Advises SILAC on Acquisition by Hildene Capital Management
December 10, 2025
Mintz advised SILAC, Inc., the parent company of SILAC Insurance Company (“SILAC”), a leading provider of fixed and fixed indexed annuity products in the US, on its definitive agreement to be acquired by Hildene Capital Management, an $18+ billion credit-focused alternative asset manager, for approximately $550 million in cash.
Mintz Advises on Capricor Therapeutics’ $150 Million Public Offering
December 10, 2025
Mintz advised the underwriters in connection with Capricor Therapeutics’ $150 million public offering.
FCA Bar Eager to Scrutinize 11th Circ. Qui Tam Debate
December 9, 2025
Comments from White Collar Defense and Government Investigations Practice Co-chair Eóin Beirne and Associate Grady Campion were featured in a Law360 Healthcare Authority article previewing oral arguments in an Eleventh Circuit case challenging the False Claims Act’s whistleblower provisions. Depending on how the circuit panel approaches the issues, the matter could ultimately reach the Supreme Court.
Mintz Advises Relation Therapeutics on Additional Funding Round, Including Strategic Investment from Novartis
December 09, 2025
Mintz advised Relation Therapeutics, a technology-enabled biopharmaceutical company, on its strategic collaboration with Novartis, leading on the negotiation of an equity investment from Novartis.
Mintz’s Tara Dunn Jackson Named to Massachusetts Lawyers Weekly’s 2025 Top Women of Law
December 04, 2025
Mintz Associate Tara Dunn Jackson has been named to Massachusetts Lawyers Weekly’s 2025 Top Women of Law list, which honors the achievements of exceptional women lawyers who are pioneers, educators, trailblazers, and role models. The honorees were recognized at a ceremony hosted by Massachusetts Lawyers Weekly in November.
Lawyers Adapt to Crop of New FDA Pilots
December 2, 2025
Joanne Hawana shared insights with Law360 Healthcare Authority about how drugmakers are responding to a series of pilot programs launched by the Food and Drug Administration. The new programs include an AI-assisted scientific review process and a program designed to accelerate the drug approval process, among other changes.
